Amorphous Drug Solubility and Maximum Free Drug Concentrations in Cyclodextrin Solutions: A Quantitative Study Using NMR Diffusometry
The effect of CD on the amorphous drug solubility and the maximum thermodynamic activity of the drug in the aqueous
Tag: HPBCD
Nanofibrous Formulation of Cyclodextrin Stabilized Lipases for Efficient Pancreatin Replacement Therapies
The purpose of enzyme therapies (ERT) is simple: patients who suffer from enzyme deficiency should be treated by administering enzymes
Influence of Substitution Groups on the Inclusion Complexation of β-Cyclodextrin
Molecular dynamic (MD) simulations have been performed to investigate the inclusion behavior of anthracene (ANT) into three kinds of CDs,
Mallinckrodt gave up further development of adrabetadex (VTS-270; HPBCD)
Mallinckrodt Pharmaceuticals has reached an agreement to divest and transfer the Investigational New Drug (IND) application for experimental drug adrabetadex
HPBCD in vaccine development
Pharmaceutical Technology has published an evaluation from experts on vaccine development. According to recent market research, the vaccines market is
Molecular lipophilic potential of cyclodextrins
A recent review of Jicsinszky et al. (2021) gave an overview on cyclodextrins’ benefits and limitations in various antiviral drug
The Role of Cyclodextrins against Interface-Induced Denaturation in Pharmaceutical Formulations
Protein-based pharmaceutical products are subject to a variety of environmental stressors, during both production and shelf-life. In order to preserve
Antibiotic-in-cyclodextrin-in-liposomes: formulation development and interactions with model bacterial membranes
Gram-negative bacteria possess numerous defenses against antibiotics, due to the intrinsic permeability barrier of their outer membrane, explaining the recalcitrance
CD as Drug: Hydroxypropyl Cyclodextrin Improves Amiodarone-induced Aberrant Lipid Homeostasis of Alveolar Cells
Alveolar epithelial type II (AT2) cells secrete pulmonary surfactant via lamellar bodies (LBs). Abnormalities in LBs are associated with pulmonary
Inhaled budesonide in the treatment of early COVID-19
The Lancet published on an open-label, parallel-group, phase 2, randomised controlled trial, on inhaled budesonide (Ramakrishnan et al. 2021). Participants